Brightlands Venture Partners is an independent venture capital firm based in Geleen, Netherlands, founded in 2014. The firm focuses on investing in sectors such as renewable chemistry, circularity, regenerative medicine, biomedical materials, agritech, food, and digital technologies. As an ecosystem investor, Brightlands Venture Partners primarily seeks opportunities in companies linked to the Brightlands campuses, fostering innovation within the region. The firm manages several funds, including Limburg Ventures, Chemelot Ventures, and Brightlands Agrifood Fund, which are largely privately funded but supplemented with public financing to enhance their investment capacity. The firm emphasizes environmental, social, and governance (ESG) criteria in its investment strategy and aims to support companies that drive positive impact in their respective fields.
Grassa BV specializes in the valorization of plant-based streams through bioraffinage, focusing on extracting value from grass and other agricultural residues. The company utilizes mobile refining machines to process fresh grass from pastures, agricultural by-products, invasive aquatic plants, and natural grass from conservation areas. This innovative approach yields four key products: fibers, protein, phosphate, and whey (liquid byproduct). Grassa's technology not only enhances the utility of these plant materials but also supports farmers by providing access to advanced solutions that help address food scarcity and improve their income stability.
PL BioScience
Series A in 2024
STEM CELL EXPANSION IN SAFE AND REPRODUCIBLE CONDITIONS. We deliver advanced 2D and 3D cell culture solutions based on human Platelet Lysate – for basic research, cellular therapeutics and clinical applications. Choose between different safety grades meeting your needs: Research Grade, GMP Grade or GMP-Clinical Grade.
Vivalyx
Seed Round in 2024
Vivalyx Omnisol is a healthcare company dedicated to enhancing organ transplantation processes. It offers a comprehensive solution for organ preservation that utilizes patented technology to improve organ vitality and increase the number of available organs for transplantation. The company's approach eliminates the need for blood or human products, making it a cost-effective and efficient option for addressing organ failure. By focusing on the needs of patients suffering from organ failure worldwide, Vivalyx aims to support medical professionals in their efforts to improve transplant outcomes.
Qorium
Venture Round in 2024
Qorium is a biotechnology company focused on producing sustainable, cell-cultured collagen-based leather. By utilizing advanced cell culturing and tissue engineering technologies, Qorium aims to minimize the environmental impact associated with traditional leather manufacturing. The company's innovative approach provides a premium alternative to conventional leather, which is often linked to issues such as deforestation and the meat industry. As a result, Qorium offers a viable option for consumers seeking animal-free leather products while promoting sustainability in the fashion and materials industries.
Matisse Pharmaceuticals
Venture Round in 2024
Matisse Pharmaceuticals B.V. is a biotechnology company based in Geleen, the Netherlands, specializing in the development of pharmaceutical therapies for sepsis and related inflammatory disorders. Founded in 2014, the company is advancing its lead product, M6229, a heparin fraction currently in the pre-clinical phase, aimed at treating severe sepsis and septic shock. Matisse Pharmaceuticals focuses on research and development efforts to create therapies that neutralize harmful components of the inflammatory system, ultimately enhancing treatment options for healthcare professionals and improving patient outcomes.
Corporis
Series B in 2023
Corporis Medical is a medical device company focused on developing and commercializing innovative diagnostic tools for minimally invasive surgical procedures, particularly in laparoscopic and bowel surgery. The company aims to enhance surgical outcomes by preventing anastomotic leakages, allowing surgeons to assess the quality of the anastomosis during operations. By improving surgical techniques and outcomes, Corporis Medical contributes to reducing postoperative complications and lowering overall healthcare costs.
ReSolved Technologies
Seed Round in 2023
ReSolved Technologies are dedicated to increase the circularity of engineering plastics by addressing complex waste streams. They do this by extracting valuable plastics from these difficult-to-recycle waste streams and convert them to recycled material of near-virgin quality that is suited for closed-loop recycling in high-end markets.
Circularise
Series A in 2022
Circularise is a provider of digital product passports and mass balance bookkeeping software, focusing on sustainability and supply chain transparency. The company’s software assists suppliers, manufacturers, recyclers, and brands across various industries, including chemicals, plastics, battery materials, and metals, in tracing materials and sharing environmental data securely. Its primary offering, the digital product passport, provides detailed records of a product's origin, material composition, and environmental impact, supported by a blockchain-based chain of custody to ensure data security. This transparency allows companies to assess their Scope 3 emissions and align with emerging regulations related to climate risk disclosure and sustainability reporting. Additionally, Circularise offers tools for Life Cycle Assessments and calculating Product Carbon Footprints, aiding clients in establishing credible environmental impact records. The MassBalancer solution facilitates compliance with certifications, enabling efficient material management and sustainability declaration generation. With a focus on data privacy, Circularise's patented Smart Questioning feature empowers clients to control the sharing of sensitive information regarding sourcing, carbon footprints, and human rights issues, thereby minimizing manual errors and enhancing operational efficiency.
Greencovery
Seed Round in 2022
Greencovery specializes in food upcycling technology that enables food companies to produce sustainable ingredients from side-stream production. The company focuses on accelerating the time-to-market for new components recovered from these side streams, thus enhancing the feasibility and sustainability of its customers' businesses. Greencovery's proprietary technology allows for the recovery of valuable ingredients that would otherwise remain unutilized, resulting in natural and upcycled products with a low carbon footprint. The offerings include savoury flavours, supplements such as amino acids, proteins, fruity flavours, and fibers, catering to markets like sports nutrition, beverages, and protein alternatives. By facilitating effective recovery of valuable products, Greencovery supports food manufacturers in creating more sustainable and functional food ingredients.
S+dB
Seed Round in 2022
S+dB is a developer of a plant seed-embedding technology to improve seed germination, seedling establishment, seed handling, and sowing. The company's SET platform technology supports seed growth during germination and its critical establishment phase and reduces the effect of nature’s bio-stresses, boosts seed vigor, and guarantees uniform growing crops with a strong root foundation. It also has the weed-controlling capacity and protects lawns from shadow yards and robust playing pitches that can be applied for various concepts and is easily scalable.
niostem
Seed Round in 2022
Niostem is a venture-funded startup focused on addressing hair loss through innovative wearable regenerative technologies. The company leverages the natural healing and regenerative capabilities of adult stem cells to develop a smart device aimed at stimulating hair growth and halting hair loss, particularly in individuals experiencing male pattern baldness. By reactivating the body's physiological mechanisms for hair regeneration, Niostem's technology offers a non-invasive alternative to traditional treatments, allowing users to combat hair loss without relying on medications or invasive procedures.
Verdify
Seed Round in 2021
Verdify is a foodtech company that specializes in developing software designed to personalize online meal inspiration. Its platform allows users to create a fully customized experience by tailoring recipe content to individual nutrition profiles and lifestyle preferences. Verdify's application enables users to convert traditional recipes into alternative versions, such as plant-based or gluten-free, and facilitates the integration of food brands into online recipe content. By helping individuals set up personal food profiles that address specific dietary needs, Verdify empowers users to make informed food choices that align with their health goals and preferences.
Neuroplast
Series B in 2021
Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.
Vertoro
Series A in 2021
Vertoro specializes in converting woody and agricultural residues into a diverse array of bio-based chemicals, materials, and fuels. The company produces crude lignin oil and crude sugar oil from these residues, providing a sustainable alternative to fossil resources. This bio-based oil serves as a liquid raw material for the petrochemical industry and offers a viable substitute for fossil crude oil in the production of various materials, chemicals, and fuels. By focusing on sustainable practices, Vertoro aims to deliver a universal biofuel source that supports the transition towards greener energy solutions.
Qorium
Venture Round in 2021
Qorium is a biotechnology company focused on producing sustainable, cell-cultured collagen-based leather. By utilizing advanced cell culturing and tissue engineering technologies, Qorium aims to minimize the environmental impact associated with traditional leather manufacturing. The company's innovative approach provides a premium alternative to conventional leather, which is often linked to issues such as deforestation and the meat industry. As a result, Qorium offers a viable option for consumers seeking animal-free leather products while promoting sustainability in the fashion and materials industries.
Black Bear Carbon
Venture Round in 2021
Carbon black is a form of elemental carbon that is manufactured by the controlled vapour-phase pyrolysis and partial combustion of hydrocarbons. Several processes have been used to produce carbon black, including the oil-furnace, impingement (channel), lampblack, thermal (decomposition of natural gas) and acetylene (decomposition) processes. Carbon blacks are commonly referred to by the process or the source material from which they are made, e.g. furnace black, lampblack, thermal black, acetylene black and channel black. The different grades from the various processes have certain unique characteristics, but it is now possible to produce reasonable approximations of most of these grades using the oil-furnace process, by which more than 95% of the total output of carbon black is produced.
Neuroplast
Funding Round in 2020
Neuroplast is a biotechnology company that focuses on developing personalized neuro-regenerative medicine. The company aims to bring qualified autologous stem cell products to the global market, specifically targeting the treatment of spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries. By isolating, manufacturing, and reinserting patients' own cells, Neuroplast enhances the potential for successful therapies that improve the quality of life for individuals suffering from these conditions. The company recognizes the need for dedicated standards and regulations in the field of neuro-regenerative medicine to ensure effective and safe treatment options.
AvL Motion
Seed Round in 2019
AvL Motion BV, based in Overloon, the Netherlands, specializes in developing autonomous harvesting robots aimed at automating the labor-intensive process of selective crop harvesting. The company's flagship product is a selective asparagus harvester, designed to efficiently harvest white asparagus, with applications also extending to other crops such as green asparagus and zucchini. By introducing advanced technology into horticulture, AvL Motion seeks to enhance industrial automation within the agricultural sector, allowing small and medium-sized enterprises to benefit from improved labor efficiency and process optimization.
Vacis
Venture Round in 2019
Vacis is a leading tissue engineering company focused on developing innovative solutions for vascular surgery. The company specializes in creating in situ tissue-engineered blood vessels, addressing a significant challenge in the field: the frequent failure of prosthetic vascular grafts, which often leads to complications and increased healthcare costs. Vacis's technology employs a synthetic rod with a specialized surface, which, when inserted under the skin, stimulates the body to form a tissue capsule that matures into a functional blood vessel. This process allows for the creation of autologous graft vessels that offer sustained patency and reduce the need for corrective interventions, ultimately providing patients with safer and more effective options for vascular access, particularly in hemodialysis.
Grassa
Series A in 2019
Grassa BV specializes in the valorization of plant-based streams through bioraffinage, focusing on extracting value from grass and other agricultural residues. The company utilizes mobile refining machines to process fresh grass from pastures, agricultural by-products, invasive aquatic plants, and natural grass from conservation areas. This innovative approach yields four key products: fibers, protein, phosphate, and whey (liquid byproduct). Grassa's technology not only enhances the utility of these plant materials but also supports farmers by providing access to advanced solutions that help address food scarcity and improve their income stability.
Hy2Care
Series A in 2019
Hy2Care BV is a start-up based at the University of Twente in the Netherlands, focused on developing a groundbreaking treatment for osteoarthritis, a condition affecting over 100 million patients in the Western world. The company's primary product is an injectable hydrogel, designed to repair cartilage defects, particularly in the knee. This bioresorbable hydrogel consists of a two-component system made from natural polymer conjugates that undergo a mild enzymatic reaction to create a functional repair solution for cartilage damage. Hy2Care aims to significantly improve the quality of life for individuals suffering from osteoarthritis by providing an effective and innovative treatment option.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.